ANZCTR search results

In patients in whom intubation of the airway is predicted to be difficult, a C-MAC D-blade videolaryngoscope™ (Karl Storz Endoscopy, Tuttlingen, Germany) is commonly used to improve visualisation of the Glottis. Due to the high angulation of the D-Blade it is not uncommon to encounter a "can see, cannot intubate" situation, This study will compare the intubation times of two airway adjuncts used with the CMAC D-blade - the Construct Medical Flexible Tip Bougie, and the GlideRite rigid stylet, We hypothesise that the flexible tip bougie will offer improved speed of intubation owing to its ability to adjust the direction of the bougie tip during the intubation.

The purpose of this study is to evaluate how a drug moves around the body. The drug is called C595 Mab and will be combined with some existing radioactive chemicals routinely used in cancer imaging, called 99mTc and 111In. Who is it for? You may be eligible for this study if you are aged 18 or older with locally advanced or metastasised pancreatic cancer. Study details All participants in this study will have their scheduled biopsy. After laboratory testing confirms eligibility, participants will receive an injection of C595 Mab with 99mTc through a needle in the arm. Participants will then have a one CT scan. Depending on the results, after two weeks new participants will have an injection of C595 Mab with 111In through a needle in the arm, and three CT scans. Participants that will receive either 99mTc or 111In injections will have their vital signs (like temperature, blood pressure, heart rate and pulse) monitored for a few hours after their injection. It is hoped this research will help provide further information on the safety and usefulness of C595 as part of a potential future therapy for pancreatic cancer.

This pilot randomised crossover study will seek to recruit volunteers with interstitial lung disease experiencing significant cough and dyspnoea. These volunteers will be administered nebulised furosemide in the context of exercise induced dyspnoea, with nebulised normal saline being used as a control. The response of the participants’ cough and dyspnoea to the administration of these agents will be recorded and compared. It is our hypothesis that the administration of nebulised furosemide will symptomatically improve the cough and dyspnoea experienced.

The purpose of this study is to investigate the efficacy and safety of Ivosidenib and Enasidenib in patients with acute myeloid Leukaemia or myelodysplastic syndrome (MDS). Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with AML or MDS with either an IDH1 or IDH2 mutation, with no previous chemotherapy treatment. Study details Participants in this study will receive the following treatments: 1.Up to two cycles of Induction: Cytarabine for 6 days and Daunorubicin once a day for 3 days through an infusion in the vein. You will be randomly assigned either a placebo (no treatment) or Enasidenib or Ivosidenaib orally with a tablet once a day for the whole cycle. 2.Up to three cycles of consolidation: Cytarabine twice a day through an infusion in the vein over 3 days. You may then receive either a placebo (no treatment) or Enasidenib or Ivosidenaib orally with a tablet once a day until the end of consolidation. 3.Maintenance treatment will be either a placebo (no treatment), Enasidenib or Ivosidenaib for up to two years. All participants will undertake blood tests, bone marrow biopsies, scans and questionnaires.

Registry of patients with biopsy-proven renal disorders enabled by a collaboration of the State Wide Clinical Renal Network , Renal Physicians from Hospital and Health Services across Pathology Queensland and CKD.QLD,The University of Queensland and governed by a steering committee. The principal aim of the Registry is to improve patient care and outcomes. The Registry will do this by profiling renal biopsy proven disorders in Queensland which will facilitate early recognition, benchmark management to best practice, and provide a platform to validate new care strategies. Specific objectives include: 1.Development of a prospective collection of clinical, laboratory, pathology, treatment and outcome data of patients with biopsy proven medical renal disease 2.Consolidation of data into a collated data set [Registry] 3.Evaluation of patient data to identify and facilitate improved clinical care and management 4.Support clinical research 5.Identification and development of health policies targeting patients with biopsy proven renal disorders 6.Develop links and collaborations with other registries nationally and internationally

Often research to improve the care of children after surgery involves following up patient recovery at home. Until now this has been done at Perth Children's Hospital by telephone interview, however telephone follow-up is time consuming and might be inconvenient for families. We will test an automated interactive SMS messaging system to communicate with families about their child’s pain at home after tonsillectomy with 100 families. We expect that this will be easier for researchers and more convenient for families, and that we will be able to contact more families successfully using this method.

There is a 25% failure rate for peripheral intravenous catheters (PIVC) inserted for infants and children requiring treatment within the emergency department and during hospitalisation. Our trial aims to test if new advances in catheter securement, medical grade superglue and an integrated dressing securement product are effective at preventing cannula failure and complications in paediatric patients. The outcome we are measuring is the decrease in failure rate between standard treatment and our new securement devices.

This randomised study compared how tibial fixation affected component migration, bone remodelling and clinical outcomes in Posterior Stabilised Total Knee Replacements. 100 patients were randomised to receive TKRs with cemented or cementless tibial components. The hypothesis was that tibial fixation method would impact implant stability.

The primary aims of this first-in-human study are to investigate the safety and immunogenicity of ACT-1239, a Vaccine for Plasmodium falciparum Malaria. Up to 50 participants will be recruited to five Cohorts of 10 participants each in this open-label, dose escalation, first in human (FIH) study. Participants will receive an intramuscular (IM) injection of ACT-1239 at the specified dose level per their allocated treatment group. Two sentinel participants of each Cohort will be dosed initially. If dosing of these sentinel participants proceeds without clinically-significant adverse events (AEs) over a 24 hour period, the remaining 8 participants of that Cohort will be dosed. Participants will receive a total of 3 IM vaccinations, administered 28 days apart. The dose level will be established following assessment of safety data of the preceding cohorts but is planned to increase from 1µg (Cohort 1) to 3µg (Cohort 2), 10µg (Cohort 3), 30µg (Cohort 4) and 100µg (Cohort 5). Participants will be followed up post-vaccinations via phone call and clinic visits up until Day 85 following vaccination number 3 ( the last administered vaccination) for safety and other assessments. Participants will then be required to return to the site at 6 and 12 months for safety follow up.

Atherosclerotic plaques are a major contributor to ischaemic strokes. While magnetic resonance imaging (MRI), duplex ultrasonography, computer tomography (CT) and angiographic investigations can detect atherosclerosis, there is currently no method to accurately determine which plaques are most likely to cause clinical events, or alternatively, which plaques are stable. Identifying “vulnerable” plaques, irrespective of the degree of stenosis, is therefore a key aim of vascular researchers. It is suggested that vulnerable plaques have a higher degree of hypoxia than asymptomatic plaques. FMISO is a tracer known to accumulated in hypoxic regions. The proposed project is a pilot study that aims to utilize FMISO for carotid artery imaging to determine whether it can distinguish between vulnerable and stable plaques This study will recruit patients at Royal North Shore Hospital who have had previous stroke and undertake FMISO PET scans of their carotid arteries. It will compare them to PET images from patients who have plaque but who have not had ischaemic events in order to ascertain whether positive PET scans correlate with symptomatic plaques compared to negative controls who have no history of TIA.